NFKB1 and metabolic dysfunction-associated steatohepatitis: This indicates that the GSDMD-N terminal fragment shows promise as a potential biomarker for NASH diagnosis, highlighting the significant role of GSDMD in NASH development by regulating lipogenesis, inflammatory responses, and the NF-κB signaling pathway.